 |
Prospector
Profile
1018-06
|
| |
| IsoRay, Inc. |
NAICS |
541710 |
| 350 Hills Street, Suite 106
Richland, WA 99352 |
Description |
Biotechnology |
| (509) 375-1202 |
Employees |
0 |
| http://www.isoray.com/ |
Revenue |
(mil) |
5.7380 |
| |
Income |
(mil) |
-9.6050 |
| |
Assets |
(mil) |
26.0760 |
| |
Liability |
(mil) |
3.3590 |
| |
(for the year ended 2007-06-30) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
IsoRay, Inc. reported a net loss of $9,605,155 on revenues of $5,738,033 for the year ended June 30, 2007, higher than the $8,218,130 net loss on revenues of $1,944,306 reported during the previous fiscal year. The Company also used cash for operating activities of $7,201,710 for the year ended June 30, 2007, compared to $7,003,077 used for operating activities during the previous fiscal year. The Company's balance sheet at June 30, 2007 showed an accumulated deficit of $23,151,416.
|
| |
|
Intellectual Property:
The Company relies on a combination of patent, copyright and trademark laws, trade secrets, software security measures, license agreements and nondisclosure agreements to protect its proprietary rights. A patent for the cesium separation and purification process was granted on May 23, 2000 by the U.S. Patent and Trademark Office under Patent Number 6,066,302. The process was developed by Lane Bray and has been assigned exclusively to IsoRay. IsoRay’s predecessor also filed for patent protection in four European countries under the Patent Cooperation Treaty. Those patents have been assigned to IsoRay. The Company also filed five patent applications relating to methods of deriving Cs-131 developed by IsoRay employees. The Company is currently working on developing and patenting additional methods of deriving Cs-131 and other isotopes. [SEC Filing 10-KSB 09-28-07]
|
| |
|
Description:
The Company, through its subsidiary, IsoRay Medical, Inc., engages in the production and development of brachytherapy seed for the treatment of prostrate cancer and other solid cancer tumors in the United States and Europe.
|
| |
|
Officers:
Roger Girard (Chair, Pres. & CEO); Jonathan Hunt (CFO & Treas.); David Swanberg (EVP, Sec. & Dir.); Robert Kauffman (Dir.); Thomas LaVoy (Dir.); Stephen Boatwright (Dir.); Dwight Babcock (Dir.); Albert Smith (Dir.)
|
| |
|
Auditor:
DeCoria Maichel & Teague PS
|
| |
|
Securities:
Common Stock-Symbol ISRY.OB; OTC BB;
23,033,108 common shares outstanding as of September 12, 2007.
|
| |
| |
| |
| return to main page |
|
|
